Literature DB >> 22589551

The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells.

Xiufen Li1, Jinqiu Kuang, Yi Shen, Martin M Majer, Chad C Nelson, Krishna Parsawar, Karen A Heichman, Scott K Kuwada.   

Abstract

Because HER-2 has been demonstrated in the nuclei of cancer cells, we hypothesized that it might interact with transcription factors that activate ERBB2 transcription. Macrohistone 2A1 (H2AFY; mH2A1) was found to interact with HER-2 in cancer cells that overexpress HER-2. Of the two human mH2A1 isoforms, mH2A1.2, but not mH2A1.1, interacted with HER-2 in human cancer cell lines. Overexpression of mH2A1.2, but not mH2A1.1, in cancer cells significantly increased HER-2 expression and tumorigenicity. Inhibition of HER-2 kinase activity diminished mH2A1 expression and mH2A1.2-induced ERBB2 transcription in cancer cells. Chromatin immunoprecipitation of mH2A1.2 in cancer cells stably transfected with mH2A1.2 showed enrichment of mH2A1.2 at the HER-2 promoter, suggesting a role for mH2A1.2 in driving HER-2 overexpression. The evolutionarily conserved macro domain of mH2A1.2 was sufficient for the interaction between HER-2 and mH2A1.2 and for mH2A1.2-induced ERBB2 transcription. Within the macro domain of mH2A1.2, a trinucleotide insertion (-EIS-) sequence not found in mH2A1.1 was essential for the interaction between HER-2 and mH2A1.2 as well as mH2A1.2-induced HER-2 expression and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589551      PMCID: PMC3391143          DOI: 10.1074/jbc.M112.379412

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Multiple facets of the unique histone variant macroH2A: from genomics to cell biology.

Authors:  Matthew J Gamble; W Lee Kraus
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

2.  Splicing regulates NAD metabolite binding to histone macroH2A.

Authors:  Georg Kustatscher; Michael Hothorn; Céline Pugieux; Klaus Scheffzek; Andreas G Ladurner
Journal:  Nat Struct Mol Biol       Date:  2005-06-19       Impact factor: 15.369

3.  The histone variant macroH2A1 marks repressed autosomal chromatin, but protects a subset of its target genes from silencing.

Authors:  Matthew J Gamble; Kristine M Frizzell; Christine Yang; Raga Krishnakumar; W Lee Kraus
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

4.  EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

Authors:  Gianmaria Liccardi; John A Hartley; Daniel Hochhauser
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

Review 5.  The HER-2/neu oncogene in tumors of the gastrointestinal tract.

Authors:  J S Ross; B J McKenna
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

6.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.

Authors:  Neali D Hendrix; Rong Wu; Rork Kuick; Donald R Schwartz; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

7.  Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues.

Authors:  U Marti; C Ruchti; J Kämpf; G A Thomas; E D Williams; H J Peter; H Gerber; U Bürgi
Journal:  Thyroid       Date:  2001-02       Impact factor: 6.568

8.  Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.

Authors:  R Sadasivan; R Morgan; S Jennings; M Austenfeld; P Van Veldhuizen; R Stephens; M Noble
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

9.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

10.  Deciphering cellular states of innate tumor drug responses.

Authors:  Esther Graudens; Virginie Boulanger; Cindy Mollard; Régine Mariage-Samson; Xavier Barlet; Guilaine Grémy; Christine Couillault; Malika Lajémi; Dominique Piatier-Tonneau; Patrick Zaborski; Eric Eveno; Charles Auffray; Sandrine Imbeaud
Journal:  Genome Biol       Date:  2006-03-15       Impact factor: 13.583

View more
  19 in total

Review 1.  Histone variants: emerging players in cancer biology.

Authors:  Chiara Vardabasso; Dan Hasson; Kajan Ratnakumar; Chi-Yeh Chung; Luis F Duarte; Emily Bernstein
Journal:  Cell Mol Life Sci       Date:  2013-05-08       Impact factor: 9.261

2.  Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness.

Authors:  Etienne Dardenne; Sandra Pierredon; Keltouma Driouch; Lise Gratadou; Magali Lacroix-Triki; Micaela Polay Espinoza; Eleonora Zonta; Sophie Germann; Hussein Mortada; Jean-Philippe Villemin; Martin Dutertre; Rosette Lidereau; Stéphan Vagner; Didier Auboeuf
Journal:  Nat Struct Mol Biol       Date:  2012-09-30       Impact factor: 15.369

Review 3.  Macro domains as metabolite sensors on chromatin.

Authors:  Melanija Posavec; Gyula Timinszky; Marcus Buschbeck
Journal:  Cell Mol Life Sci       Date:  2013-03-03       Impact factor: 9.261

Review 4.  Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Authors:  Rosalía I Cordo Russo; María F Chervo; Santiago Madera; Eduardo H Charreau; Patricia V Elizalde
Journal:  Horm Cancer       Date:  2019-01-17       Impact factor: 3.869

Review 5.  Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.

Authors:  Mei-Kuang Chen; Mien-Chie Hung
Journal:  FEBS J       Date:  2015-07-04       Impact factor: 5.542

6.  Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth.

Authors:  María F Chervo; Rosalía I Cordo Russo; Ezequiel Petrillo; Franco Izzo; Mara De Martino; Nicolás Bellora; Mauro E Cenciarini; Violeta A Chiauzzi; Lucía Santa María de la Parra; Matías G Pereyra; Leandro N Güttlein; Osvaldo L Podhajcer; José L Daniotti; Agustina Dupont; Sabrina Barchuk; Silvina Figurelli; Daniel Lopez Della Vecchia; Juan C Roa; Pablo Guzmán; Cecilia J Proietti; Roxana Schillaci; Patricia V Elizalde
Journal:  Oncogene       Date:  2020-08-25       Impact factor: 9.867

Review 7.  Every amino acid matters: essential contributions of histone variants to mammalian development and disease.

Authors:  Ian Maze; Kyung-Min Noh; Alexey A Soshnev; C David Allis
Journal:  Nat Rev Genet       Date:  2014-03-11       Impact factor: 53.242

8.  Functional annotation of colon cancer risk SNPs.

Authors:  Lijing Yao; Yu Gyoung Tak; Benjamin P Berman; Peggy J Farnham
Journal:  Nat Commun       Date:  2014-09-30       Impact factor: 14.919

9.  Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy.

Authors:  Ann Rita Halvorsen; Aslaug Helland; Thomas Fleischer; Karen Marie Haug; Grethe Irene Grenaker Alnaes; Daniel Nebdal; Randi G Syljuåsen; Nizar Touleimat; Florence Busato; Jörg Tost; Anna B Saetersdal; Anne-Lise Børresen-Dale; Vessela Kristensen; Hege Edvardsen
Journal:  Int J Cancer       Date:  2014-04-05       Impact factor: 7.396

Review 10.  Expression and functionality of histone H2A variants in cancer.

Authors:  Fátima Liliana Monteiro; Tiago Baptista; Francisco Amado; Rui Vitorino; Carmen Jerónimo; Luisa A Helguero
Journal:  Oncotarget       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.